Japan's Ono Pharmaceutical Co said on Tuesday its $2.4 billion takeover of Deciphera Pharmaceuticals is a "first step" in expanding in U.S. and European markets. With this deal, Ono Pharma joins Japanese rivals Takeda Pharmaceutical and Astellas Pharma which have spent big recently to replenish their drug pipelines. Ono Pharma is best known globally for its blockbuster cancer drug Opdivo, which is sold in the U.S. by partner Bristol-Myers Squibb.
On Monday, Japanese pharma company ONO Pharmaceutical agreed to acquire Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) for $25.60 per share in cash, for a total equity value of $2.4 billion. Deciphera brings specialized research and development capabilities in kinase drug discovery, well-established commercial and sales platforms in the United States and Europe, and global clinical development capabilities. In addition to QINLOCK – Deciphera’s switch-control inhibitor for the treatment of fourth-li
Deciphera Pharmaceuticals is being bought by Japan’s ONO Pharmaceutical in a deal valued at $2.4 billion.